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Introduction
Premature rupture of membranes (PROM) at term is
described as the rupture of membranes prior to the
onset of labor at or beyond 37 weeks of gestation.
Approximately 10% of term pregnancies are compli-
cated with PROM. Patients with PROM complain of
fluid leakage, vaginal discharge, vaginal bleeding and
pelvic pressure without any contractions [1,2].
Nearly 90% of women enter spontaneous labor
within 24 hours when they experience PROM at term.
The major question regarding the management of
patients with PROM is whether to allow them to enter
labor spontaneously or to induce labor. Although the
management of patients with PROM usually depends
on their personal wish, the major maternal risk at this
gestational age is intrauterine infection [3,4].
The neonatal risks associated with expectant man-
agement of PROM include infection, placental abrup-
tion, fetal restriction deformities, pulmonary hypoplasia,
distress, and related fetal/neonatal death. Fetal death
occurs in about 1 in 1,000 women with term PROM who
have been expectantly managed. Because the risk of
intrauterine infection increases with the duration of
PROM, the induction of labor decreases the risk of cho-
rioamnionitis, without changing the rate of cesarean
delivery, as opposed to expectant management [1–4].
The sustained-release prostaglandin E2 (PGE2) vagi-
nal insert has been shown to be safe and efficacious in
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SUMMARY
Objective: The aim of this study was to compare the efficacy and safety of a prostaglandin E2 (PGE2) vaginal insert
with those of oxytocin for labor induction. The present study also examined whether its use reduces the rate of
cesarean delivery in term pregnancies with premature rupture of membranes (PROM) and low Bishop scores.
Materials and Methods: A total of 240 women with singleton pregnancies at ≥ 37 weeks, no prior uterine scar,
vertex presentations, reactive nonstress tests, PROM for ≥ 12 hours and Bishop scores of ≤ 6 were randomly
assigned to receive either oxytocin or vaginal PGE2. The primary outcomes were time from induction to delivery
and mode of delivery.
Results: The time from labor induction to active labor onset was significantly shorter in the oxytocin group than
in the PGE2 group (4.9 ± 4.1 vs. 8.5 ± 3.6 hours; p = 0.02). The time from induction to delivery was also signifi-
cantly shorter in the oxytocin group (3.4 ± 1.5 vs. 9.6 ± 4.7 hours; p = 0.02). Cesarean delivery rates were statisti-
cally similar in the oxytocin and PGE2 groups (18.3 vs. 20.0%; p = 0.81). Neonatal outcomes were comparable in
both groups. Comparable results were observed for nulliparous women included in the study population.
Conclusion: Oxytocin treatment seems to be superior to vaginal administration of PGE2 to induce labor in term
pregnancies complicated with PROM and unfavorable services. [Taiwan J Obstet Gynecol 2010;49(1):57–61]
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promoting cervical ripening in women with term preg-
nancies and low Bishop scores [5]. However, there are
insufficient data related to the efficacy and safety of
PGE2 in term pregnancies complicated with PROM
[6,7].
Therefore, the purpose of this study was to compare
the efficacy and safety of PGE2 vaginal insert with those
of oxytocin for labor induction. The present study also
evaluated whether its use reduces the rate of cesarean
delivery in term pregnancies complicated with PROM
and low Bishop scores.
Materials and Methods
This study was approved by the ethical committee and
institutional review board of Dr Zekai Tahir Burak
Women Health and Research Hospital where the study
was conducted.
The subjects were recruited from the labor and
delivery unit between March 2007 and May 2007. A
total of 255 women with term singleton pregnancies,
cephalic presentation, PROM ≥ 12 hours, reactive non-
stress tests, no previous uterine surgery, and Bishop
scores ≤ 6 (unfavorable cervices) were eligible for the
study. All subjects gave written informed consent.
Women were excluded from the study if they had
more than six previous term pregnancies, vaginal bleed-
ing, hypersensitivity to prostaglandins, asthma, placen-
tal pathologies, more than three contractions in 10
minutes, or any other conditions that would contraindi-
cate labor induction.
Four subjects refused to participate in the study for
personal reasons; therefore, a total of 240 women
were randomly assigned to receive either a vaginal PGE2
insert or oxytocin infusion. No patients were withdrawn
because of maternal side effects such as acute bron-
chospasm or hypersensitivity reaction.
Although the PGE2 vaginal inserts are documented
to release PGE2 at a rate of 0.3 mg/hour, the rate differs
in the presence of PROM [8]. As recommended by its
manufacturer, the PGE2 insert was left in situ for 12
hours, if possible, or removed at the onset of active
labor. Active labor was defined as beginning when cer-
vical dilatation was 4 cm.
Oxytocin infusion (5 mU oxytocin in 500 mL of
Ringer’s lactate solution) was started at a rate of 2 mU/
min and increased by 2 mU/min every 20 minutes. If
contractions reached a frequency of four per 10 minutes
for two consecutive 10-minute periods, the oxytocin
dose was not increased further, unless the frequency of
contractions diminished. The maximum allowable dose
of oxytocin was 36 mU/min.
Uterine contractions were insufficient to sustain
active labor in 4.2% (five out of 120) of the subjects
treated with PGE2. Until efficient uterine contractions
were achieved, these participants received oxytocin
(5 mU oxytocin in 500 mL of Ringer’s lactate solution)
at a steady infusion rate of 2 mU/min.
Fetal heart rate (FHR) and uterine activity were mon-
itored continuously. The Bishop score was assessed and
documented every hour by the same clinician, who also
checked whether the vaginal PGE2 insert was correctly
placed and repositioned or replaced the insert when
needed. Two researchers together interpreted the traces
produced by the external electronic fetal monitors to
minimize bias.
Tachysystole was defined as six or more contrac-
tions every 10 minutes for two consecutive 10-minute
periods, and hypertonus was defined as uterine con-
traction that lasted ≥ 2 minutes. Oxytocin infusion was
decreased and the vaginal PGE2 insert was removed if
tachysystole occurred in the presence of a worrying
FHR trace.
Hyperstimulation was described as an exaggerated
uterine response with late FHR decelerations or fetal
tachycardia (> 160 beats/min) or other worrying FHR
changes. In the event of hyperstimulation, the oxytocin
infusion was stopped and the vaginal PGE2 insert 
was removed, and fetal resuscitation (and tocolysis, if
needed) was done.
Despite 12 hours of continuous treatment with the
PGE2 insert, active labor failed to occur in four subjects.
To avoid bias and confusion during the interpretation
of data, no other method of labor induction methods
was used, and for these cases, “failed induction” was
reported as the indication for cesarean delivery.
As indicated by the chemoprophylaxis guidelines of
the study center, antibiotics were administered to pre-
vent group B streptococcal infections in case PROM
lasted for ≥ 18 hours, body temperature was ≥ 38°C,
and there was a history of group B streptococcal bac-
teriuria or previous delivery of a newborn with group B
streptococcal sepsis.
Penicillin (5 million U, intravenous (IV), followed by
2.5 million U, IV, every 4 hours until delivery) was the
preferred antibiotic. For participants with known hyper-
sensitivity to penicillin, either erythromycin (500 mg, IV,
every 6 hours until delivery) or clindamycin (900 mg, IV,
every 8 hours until delivery) was preferred. None of the
subjects showed any hypersensitivity reactions to the
antibiotics for the duration of this study.
All statistical analyses were performed using
Statistical Package for Social Sciences version 11.5 soft-
ware (SPSS Inc., Chicago, IL, USA). Continuous data
are expressed as mean ± standard deviation and were
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analyzed with two-sample t tests. Categorical data were
analyzed with χ2 test. A p value of < 0.05 represented
statistical significance.
Results
Overall, 120 subjects received a vaginal PGE2 insert and
120 women received oxytocin infusion. Table 1 shows
the preinduction characteristics of the study popula-
tion. The proportion of nulliparous women were simi-
lar in the PGE2 and oxytocin groups (90/120 [75.0%]
vs. 80/120 [66.7%]; p = 0.54). Table 2 summarizes the
clinical outcomes, and Table 3 summarizes the obstet-
ric and neonatal outcomes. There were no cases of intra-
partum chorioamnionitis or postpartum endometritis.
Table 4 summarizes the selected clinical outcomes for
nulliparous women.
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Table 1. Preinduction characteristics of the study population*
PGE2 (n = 120) Oxytocin (n = 120) p
Maternal age (yr) 24.9 ± 5.2 25.0 ± 4.4 0.96
Maternal weight (kg) 70.8 ± 7.7 71.1 ± 9.5 0.92
Maternal BMI (kg/m2) 27.1 ± 2.8 27.4 ± 3.7 0.57
Gestational age (wk) 38.7 ± 1.4 38.7 ± 1.4 0.75
Parity 0.7 ± 0.9 0.8 ± 1.2 0.21
Preinduction Bishop score 3.77 ± 1.1 3.86 ± 1.5 0.72
*Data are presented as mean ± standard deviation. PGE2 = prostaglandin E2; BMI = body mass index.
Table 2. Clinical outcomes of the study population*
PGE2 (n = 120) Oxytocin (n = 120) p
Duration of treatment (hr)† 8.5 ± 3.6 8.8 ± 2.5 0.44
Frequency of uterine contractions (/hr) 20.0 ± 10.0 22.0 ± 8.0 0.33
Mean duration of a contraction (s) 58.1 ± 12.2 63.2 ± 13.4 0.38
Bishop score change in 12 hours 5.5 ± 2.4 5.3 ± 2.1 0.88
Induction to active labor onset (hr) 8.5 ± 3.6 4.9 ± 4.1 0.02
Induction to delivery (hr) 9.6 ± 4.7 3.4 ± 1.5 0.02
Uterine hypertonicity 2 (1.7) 0 (0) 0.71
Uterine tachysystole 5 (4.2) 4 (3.3) 0.11
Uterine hyperstimulation 4 (3.3) 2 (1.7) 0.22
Need to cease treatment‡ 5 (4.2) 2 (1.7) 0.04
Need for tocolysis 2 (1.7) 0 (0) 0.71
*Data are presented as mean ± standard deviation or n (%); †duration of treatment refers to the duration of time between placement and removal of the vaginal
PGE2 insert or the beginning and termination of oxytocin infusion; 
‡the vaginal PGE2 insert was removed due to a worrying fetal heart rate trace caused by uterine
tachysystole and the oxytocin infusion was stopped due to uterine hyperstimulation. PGE2 = prostaglandin E2.
Table 3. Obstetric and neonatal outcomes of the study population*
PGE2 (n = 120) Oxytocin (n = 120) p
Cesarean delivery 24 (20.0) 22 (18.3) 0.81
Indication for cesarean delivery
Worrying FHR 15 (12.5) 13 (10.8) 0.88
Cephalopelvic disproportion 5 (4.2) 7 (5.8) 0.81
Failed induction 4 (3.3) 2 (1.7) 0.68
Mean Apgar score at 1 minute 7.0 ± 0.2 6.8 ± 0.6 0.74
Mean Apgar score at 5 minutes 9.0 ± 0.2 8.8 ± 0.6 0.73
Mean birth weight (g) 3,183.9 ± 326.5 3,202.9 ± 402.9 0.79
Admission to NICU 13 (10.8) 20 (16.7) 0.46
*Data are presented as n (%) or means ± standard deviation. PGE2 = prostaglandin E2; FHR = fetal heart rate; NICU = neonatal intensive care unit.
Discussion
Spontaneous labor is acknowledged to start within 24
hours of the rupture of fetal membranes before the onset
of labor in the majority of women [2]. However, early
induction of labor can be initiated to reduce the risk of
maternal infection and shorten the delivery time in term
pregnancies complicated with low Bishop scores and
PROM [3].
Although oxytocin is usually preferred to promote
labor in term PROM, it was recently proposed that
prostaglandins E1 and E2 can be administered vaginally
to stimulate cervical ripening in term pregnancies com-
plicated with low Bishop scores and PROM [7,9].
PGE2 is an efficacious agent that shortens the time
from induction to delivery, improves success rates and
reduces morbidity associated with labor induction.
Although PGE2 may cause abnormal uterine contrac-
tions or FHR traces, abnormal psychomotor or physical
development has not been reported in children born to
mothers given a vaginal PGE2 insert to stimulate cervical
ripening [10].
Local PGE2 administration can be carried out via
vaginal inserts, tablets or gels [11]. It has been re-
ported that vaginal PGE2 offers a reasonable, effective
and reliable option to induce labor in an outpatient
setting [12,13]. Yogev et al [13] showed that the induc-
tion of labor with a vaginal PGE2 insert was successful
in 169 out of 211 women (80.1%) with post-term preg-
nancy, without any serious maternal or fetal complica-
tions. However, the rate of cesarean section increased
significantly in subjects given a vaginal PGE2 insert.
The risk factors related to the patient and labor induc-
tion itself were stated as reasons for the excess number
of cesarean deliveries in women with prolonged preg-
nancies [14].
It has been claimed that there was a marginal
improvement in patient satisfaction when a slow-release
vaginal PGE2 insert was used instead of vaginal PGE2
gel [15]. However, Rabl et al [16] showed that vaginal
PGE2 inserts and tablets were similar in terms of effi-
cacy, safety and patient comfort. They also reported that
continuous release of PGE2 could permit controlled
induction of labor, and offer easy removal of the drug in
the event of uterine hyperstimulation [16].
Some studies have investigated the efficacy and
safety of vaginal PGE2 inserts in term pregnancies com-
plicated with PROM and low Bishop scores. In one
double-blind study, 155 nulliparas with PROM and poor
cervical score (Bishop score, <6) were treated with either
PGE2 or placebo inserts. PGE2 inserts significantly
shortened the times from induction to active labor
onset and from induction to delivery. However, vaginal
PGE2 administration did not significantly affect the
cesarean delivery rate or neonatal outcomes [17].
In another clinical trial, a vaginal PGE2 insert was
administered to induce labor in 42 subjects with pre-
term PROM and 220 women with term PROM who
did not enter spontaneous labor after 24 hours of
expectant management. As a result, the vaginal PGE2
insert was effective in the majority of term and preterm
pregnancies complicated with PROM and low Bishop
scores, without causing any apparent serious maternal
or fetal complications. Higher number of PGE2 tablets 
used, nulliparity and heavier birth weight were signifi-
cantly associated with an increased risk of cesarean
delivery [18].
In the present study, oxytocin infusion significantly
shortened the times from induction to active labor
onset and from induction to delivery when compared
with those for the vaginal PGE2 insert. Both parameters
were significantly longer in nulliparous women treated
with oxytocin in comparison with those given the vagi-
nal PGE2 insert. The present study also showed that
vaginal administration of PGE2 did not significant affect
the rate of cesarean delivery or indications. The rates
of cesarean delivery for the PGE2 and oxytocin groups
(20.0% and 18.3%, respectively) were similar to those
of the institution calculated for the first 6 months of
2008 (19.2%).
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Table 4. Selected outcomes for nulliparous women
PGE2 (n = 90) Oxytocin (n = 80) p
Preinduction Bishop score 3.8 ± 1.4 3.8 ± 1.7 0.88
Bishop score change in 12 hours 5.6 ± 2.7 5.4 ± 2.3 0.80
Induction to active labor onset (hr) 6.9 ± 4.4 3.6 ± 4.4 0.01
Induction to delivery (hr) 9.1 ± 4.6 5.2 ± 3.4 0.03
Cesarean delivery 23 (25.6) 21 (26.3) 0.81
Mean Apgar score at 1 minute 7.3 ± 0.1 6.9 ± 0.5 0.76
Mean Apgar score at 5 minutes 9.1 ± 0.3 8.8 ± 0.4 0.75
*Data are presented as mean ± standard deviation or n (%). PGE2 = prostaglandin E2.
In term pregnancies with PROM, poor cervical scores
and no evidence of infection or obstetric complications,
the administration of PGE2 did not significantly affect
the establishment of active labor, and reduced the time
from admission to delivery, as compared with oxytocin.
Concurrent IV administration of low-dose oxytocin with
vaginal PGE2 may improve uterine contractions and
cause cervical ripening much more efficiently, such that
the cesarean delivery rates and maternal and neonatal
adverse effects are reduced [19].
Ramsey et al [20,21] found that the fetal car-
diotocographic abnormalities associated with PGE2
were less frequent and less severe than those associated
with PGE1. However, the present study demonstrated
that the changes in FHR were similar in the PGE2 and
oxytocin groups. However, FHR abnormalities were
associated with treatment withdrawal in the PGE2
group rather than in the oxytocin group, indicating
potential disadvantages of vaginal inserts.
The randomized prospective design of the present
study overcomes limitations of earlier studies by avoid-
ing biased Bishop scores, misinterpretation of FHR
traces and neglected minor maternal and fetal com-
plications. Another advantage is the relatively large
study population, which included nulliparous and
multiparous women. However, the open-label design
may limit the power of the present study. The discrep-
ancies among the primary outcomes of the cited pub-
lications and the present study might be attributed 
to differences in the study populations and study
designs.
In conclusion, vaginal PGE2 appears to be a relatively
inefficient method of inducing labor compared with
oxytocin in term pregnancies with PROM and unfavor-
able cervices. However, PGE2 may maintain uterine
contractions as effectively as oxytocin once uterine
contractions are established. As vaginal PGE2 are more
expensive, it is rational to prefer oxytocin infusion to
induce labor in term PROM accompanied with low
Bishop scores.
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